News and analysis on medical technology

BVI Names Former Insulet CEO Jim Hollingshead to Lead Eye Surgery Device Maker

The TPG-owned ophthalmic company, which raised $1 billion last year, replaces longtime chief Shervin Korangy as it expands its intraocular lens business in the US.

By News DeskJanuary 21, 20262 min read
A small foldable intraocular lens held in a plastic holder
A foldable acrylic intraocular lens for cataract surgery in its holder. The photo does not show a specific BVI product. Philos2000, CC BY-SA 3.0, via Wikimedia Commons · CC BY-SA 3.0

Key points

  • BVI appointed Jim Hollingshead, who led insulin pump maker Insulet for three years before resigning in 2025, as president and CEO.
  • Hollingshead succeeds Shervin Korangy, CEO since 2019, who will advise BVI and become a senior adviser to owner TPG Capital.
  • The change follows a $1 billion capital raise that BVI is using to speed product development and expand globally, MedTech Dive reported.

BVI, a maker of cataract and retina surgery products, has named former Insulet chief executive Jim Hollingshead as its president and CEO, the company said on Monday, according to MedTech Dive.

Hollingshead succeeds Shervin Korangy, who will continue as an adviser to BVI and begin a new role as senior adviser to TPG Capital, the private equity firm that owns the Waltham, Massachusetts, company, Vision Monday reported. Korangy joined BVI's executive team in 2017 and became CEO in 2019, according to MedTech Dive.

From insulin pumps to eye surgery

Hollingshead led Insulet, which sells the Omnipod insulin pump, for three years before resigning in 2025; he was replaced by Ashley McEvoy, the former head of Johnson & Johnson's medtech business, MedTech Dive reported. Before Insulet, he spent 12 years at ResMed, where he was president of its sleep and respiratory care business, according to the company's announcement.

"It's a privilege to join the BVI team as we build on the company's already strong momentum and launch multiple new, industry-leading platforms," Hollingshead said in the announcement.

"Jim's strategic vision, insight, and track record of innovation and transformation in the medical device industry make him an excellent fit for BVI as the company continues to advance its market leadership and scale its impact globally," said BVI chairman Ron Labrum.

A company built through acquisitions

The leadership change comes after BVI raised $1 billion in capital last year, money it is using to accelerate product innovation and expand its global footprint, MedTech Dive reported. The company makes its products at manufacturing sites in China, Europe, Mexico and the United States.

BVI, originally called Beaver-Visitec International, was created by private equity firm RoundTable Healthcare Partners from ophthalmology products acquired from Aspen Surgical, BD and Medtronic. TPG bought the company in 2016 and expanded its intraocular lens business with the acquisitions of PhysIOL Group and Benz Research & Development, according to MedTech Dive.

The FDA approved BVI's FineVision HP trifocal intraocular lens in 2025, extending its reach to the US, and the company launched the FDA-cleared Leos glaucoma system and Virtuoso, a combined phaco-vitrectomy platform for cataract and vitreoretinal procedures, Vision Monday reported. BVI competes in intraocular lenses with Alcon, Bausch & Lomb and J&J, according to MedTech Dive.

Sources

  1. BVI appoints Jim Hollingshead as CEO, MedTech Dive, January 21, 2026
  2. BVI Appoints Jim Hollingshead as President and Chief Executive Officer, Vision Monday, January 20, 2026